Pharmaceutical Products Companies By Held By Insiders
LargestBiggest EarnersMost ProfitableMost LiquidHighly LeveragedTop DividendsCapital-HeavyHighest ValuationLargest Workforce
Shares Owned By Insiders
| Shares Owned By Insiders | Efficiency | Market Risk | Exp Return | ||||
|---|---|---|---|---|---|---|---|
| 1 | SNYR | SYNERGY CHC P | 0.27 | 211.83 | 57.97 | ||
| 2 | ELAB | Elevai Labs, Common | (0.19) | 15.47 | (2.92) | ||
| 3 | VTVT | vTv Therapeutics | 0.03 | 4.03 | 0.12 | ||
| 4 | DSGN | Design Therapeutics | 0.11 | 4.99 | 0.56 | ||
| 5 | EQ | Equillium | 0.05 | 7.90 | 0.40 | ||
| 6 | EDSA | Edesa Biotech | (0.22) | 4.02 | (0.89) | ||
| 7 | VRCA | Verrica Pharmaceuticals | (0.21) | 10.35 | (2.22) | ||
| 8 | DYAI | Dyadic International | (0.05) | 3.65 | (0.20) | ||
| 9 | DMAC | DiaMedica Therapeutics | 0.12 | 2.71 | 0.32 | ||
| 10 | ELTX | Elicio Therapeutics | 0.06 | 4.94 | 0.29 | ||
| 11 | DRUG | Bright Minds Biosciences | 0.15 | 126.71 | 18.91 | ||
| 12 | VNRX | Volitionrx | 0.10 | 5.55 | 0.56 | ||
| 13 | VIGL | Vigil Neuroscience | 0.09 | 4.07 | 0.37 | ||
| 14 | VINC | Vincerx Pharma | (0.10) | 6.76 | (0.65) | ||
| 15 | VYGR | Voyager Therapeutics | 0.05 | 4.71 | 0.23 | ||
| 16 | ENGN | enGene Holdings Common | 0.10 | 5.37 | 0.54 | ||
| 17 | VERU | Veru Inc | (0.03) | 3.56 | (0.12) | ||
| 18 | NWBO | Northwest Biotherapeutics | (0.06) | 3.82 | (0.21) | ||
| 19 | DNLI | Denali Therapeutics | 0.17 | 3.23 | 0.53 | ||
| 20 | VCNX | Vaccinex | (0.03) | 8.52 | (0.27) |
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public. Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.